J Travel Med. 2021 Dec 7:taab188. doi: 10.1093/jtm/taab188. Online ahead of print.
ABSTRACT
BACKGROUND: Currently, there is limited data on long-term persistence of antibodies and boostability of intradermal (ID) rabies pre-exposure prophylaxis (PrEP) schedules. This study investigated travellers who received a primary ID PrEP schedule at least 5 years previously to determine persistence of antibodies and subsequent antibody response after one 0.1 mL ID booster dose.
METHODS: Adults (age ≥ 18 years) who had previously received ID PrEP at a specialist travel medicine clinic in Brisbane, Australia were included. At day 0, blood was collected for serology and one dose of 0.1 mL ID rabies vaccine (Verorab®) was administered. At day 7, serology was repeated. At day 14, participants were given results and enquired if they experienced adverse events following immunisation (AEFIs). Antibodies were measured using Platelia Rabies II ELISA, levels ≥0.5 EU/mL were considered antibody-positive.
RESULTS: 158 participants were included (64.6% female, median age at enrolment 56.4 years, IQR [interquartile range] 42.4-65.2 years), and median time since the primary ID PrEP was 8.5 years (IQR 6.9-11.7 years). The majority of participants (82.3%) were antibody-positive at day 0. The proportion of participants who were antibody-positive at day 0 was higher among those who were younger at primary vaccination (87.0% if aged<50 years, 75.8% of aged ≥50 years). The proportion of participants who were antibody-positive declined as median time since primary vaccination increased, though the trend was not statistically significant (p-trend = 0.187). All except one participant (99.4%) were antibody-positive after one ID booster dose. AEFIs were reported by 42.4% of participants and were mainly mild.
CONCLUSIONS: Rabies antibodies persist for many years after ID PrEP and can be rapidly boosted with a single ID dose. Future studies are needed to confirm that ID PrEP primes the immune system sufficiently so that boosters are not routinely needed, and only given in the event of a rabies-prone exposure.
PMID:34875078 | DOI:10.1093/jtm/taab188
